title: In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine A and tacrolimus based regiments.
abstract: OBJECTIVE
  Restoration of renal function after kidney transplantation (KT) is expected to improve oxidative stress (OS). However, little is known about the influence of calcineurin inhibitors on oxidized low-density lipoproteins (ox-LDL) after KT. The aim of this study was to evaluate ox-LDLs and related markers of OS, advanced oxidation protein products (AOPP) and total antioxidant status (TAS) in patients after KT on either cyclosporin A (CyA) or tacrolimus (Tac) treatment.
  
  
  METHODS
  This was a prospective, randomized, single-center 12 month study evaluating time-dependent changes in biomarkers of OS before and after KT. Twenty nine patients (mean age 54.4 ± 11.1; 55% male and 45% female) were treated with CyA (Group A) and twenty four patients (mean age 52.9 ± 9.9; 75% male and 25% female) were treated with Tac (Group B). The ox-LDL, AOPP, TAS, lipid metabolism parameters, creatinine and glomerular filtration were assessed on day 1 before KT and on days 1 and 7, and in months 1, 3, 6 and 12 after KT.
  
  
  RESULTS
  Over the 12 months, the ox-LDL for group A changed from 69.2±32.9 to 65.1±17.1 U/L (P=0.665), while AOPP significantly decreased from 233.0±159.6 to 156.5±90.1 μmol/L (P=0.025) and TAS from 1.87±0.31 to 1.68±0.20 mmol/L (P=0.030). For group B the ox-LDL changed from 62.9±29.7 to ± 61.4±14.6 U/L (P=0.168) and TAS from 1.87±0.51 to 1.68±0.20 mmol/L (P=0.168), while AOPP significantly decreased from 180.5±90.0 to 123.9±37.7 μmol/L (P=0.019).
  
  
  CONCLUSIONS
  AOPP is more sensitive than ox-LDL for assessing OS after KT. TAS values appear to be insufficiently sensitive for monitoring OS in patients after KT.
authors.affiliation: Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Czech Republic. josef.zadrazil@fnol.cz
authors.forename: Josef
authors.initials: J
authors.lastname: Zadrazil
authors.forename: Pavel
authors.initials: P
authors.lastname: Horak
authors.forename: Pavel
authors.initials: P
authors.lastname: Strebl
authors.forename: Karel
authors.initials: K
authors.lastname: Krejci
authors.forename: Marketa
authors.initials: M
authors.lastname: Kajabova
authors.forename: Petr
authors.initials: P
authors.lastname: Schneiderka
authors.forename: Jana
authors.initials: J
authors.lastname: Zapletalova
authors.forename: Adela
authors.initials: A
authors.lastname: Galandakova
authors.forename: Jitka
authors.initials: J
authors.lastname: Vostalova
authors.forename: Helena
authors.initials: H
authors.lastname: Vaverkova
mesh_terms: D000975:Antioxidants / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism*; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D001798:Blood Proteins; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D016572:Cyclosporine; D016559:Tacrolimus